The mRNA technology finds its applications in many diseases including the Covid-19 vaccine. The market for mRNA is mostly driven by the Covid-19 vaccine besides its major usage in cancer therapies. With the mutation of the coronavirus and possible spread of variants of the virus, the mRNA companies are actively engaged in developing next generation vaccines for Covid-19.
The Global mRNA Vaccine and Therapeutic Market is estimated at USD 29672.31 Million in the year 2025. The growing occurrences of chronic and infectious diseases, such as diabetes, HIV, cancer and CVDs, is one of the major key factors driving the growth of the market. The growing demand for therapeutic medicines and vaccines for Ebola, influenza, Human Immunodeficiency Virus (HIV) and other viral infections as well as inability of traditional vaccine approach to find vaccines at the critical time are also providing a boost to the market growth. Compared to conventional medicines, mRNA vaccines and Therapeutics are developed with the help of advanced technologies which are more effective against pathogens, have higher effectiveness, improved immunogenicity and require less cost to produce. Moreover, developments in the lipid nanoparticle formulations for in-vivo systemic delivery of mRNA are also creating a positive outlook for the market growth.
Covid-19 vaccines are expected to hold largest share of mRNA Vaccine and Therapeutics market. The standardisation of cancer treatment segment, during the forecast period 2026-2030 is expected to be the largest contributor to the market growth. The major reason is the increase in the number of cancer patient around the world and it becomes imperative to have a set of standards for its treatment.
North America holds the largest share of the mRNA vaccines and therapeutics market for non-Covid-19 vaccines due to the growing need to develop transformative therapeutics, increasing fund infusions, a favorable regulatory environment, and massively growing attention to establish precision medicine, among others. Rising prevalence of cancer and other diseases among the developing economies of Asia region is augmenting the demand of mRNA Vaccine and Therapeutics in APAC region.
Scope of the Report
Key Target Audience
The Global mRNA Vaccine and Therapeutic Market is estimated at USD 29672.31 Million in the year 2025. The growing occurrences of chronic and infectious diseases, such as diabetes, HIV, cancer and CVDs, is one of the major key factors driving the growth of the market. The growing demand for therapeutic medicines and vaccines for Ebola, influenza, Human Immunodeficiency Virus (HIV) and other viral infections as well as inability of traditional vaccine approach to find vaccines at the critical time are also providing a boost to the market growth. Compared to conventional medicines, mRNA vaccines and Therapeutics are developed with the help of advanced technologies which are more effective against pathogens, have higher effectiveness, improved immunogenicity and require less cost to produce. Moreover, developments in the lipid nanoparticle formulations for in-vivo systemic delivery of mRNA are also creating a positive outlook for the market growth.
Covid-19 vaccines are expected to hold largest share of mRNA Vaccine and Therapeutics market. The standardisation of cancer treatment segment, during the forecast period 2026-2030 is expected to be the largest contributor to the market growth. The major reason is the increase in the number of cancer patient around the world and it becomes imperative to have a set of standards for its treatment.
North America holds the largest share of the mRNA vaccines and therapeutics market for non-Covid-19 vaccines due to the growing need to develop transformative therapeutics, increasing fund infusions, a favorable regulatory environment, and massively growing attention to establish precision medicine, among others. Rising prevalence of cancer and other diseases among the developing economies of Asia region is augmenting the demand of mRNA Vaccine and Therapeutics in APAC region.
Scope of the Report
- The report analyses the mRNA Vaccine and Therapeutic Market by value (USD Million).
- The report analyses the mRNA Vaccine and Therapeutic Market by Product (COVID Vaccines, Infectious Disease Vaccines, Cancer Vaccines, Autoimmune Diseases and Others).
- The report analyses the mRNA Vaccine and Therapeutic Market by End User (Hospitals & Clinics, Research Organization and Others).
- The Global mRNA Vaccine and Therapeutic Market has been analysed By Region (North America Europe, Asia Pacific, LAMEA) By Country (United States, Canada, Germany, U.K, France, Switzerland, Russia, China, Japan, and India).
- The key insights of the report have been presented through the frameworks of the attractiveness of the market has been presented by region, by product, By End User.
- Also, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.
- The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include AstraZeneca Plc, Bayer Group, Boehringer Ingelheim, GlaxoSmithKline, Pfizer, Moderna, BioNtech, Sangamo Therapeutics, Crispr Therapeutics, Intellia Therapeutics.
- The report presents the analysis of mRNA Vaccine and Therapeutic market for the forecast period of 2021-2030.
Key Target Audience
- Biotechnology Companies
- Pharmaceutical and Healthcare Companies
- Consulting and Advisory Firms
- Government and Policy Makers
- Regulatory Authorities
Table of Contents
1. Report Scope and Methodology1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary
2. Strategic Recommendations
3. mRNA Vaccine and Therapeutics Market: Product Outlook
4. Global mRNA Vaccine and Therapeutics Market: Sizing and Forecast
4.1 Global mRNA Vaccine and Therapeutics Market Size, By Value, Year 2021-2030
5. Global mRNA Vaccine and Therapeutics Market Segmentation - By Product, By End User
5.1 Competitive Scenario of Global mRNA Vaccine and Therapeutics Market: By Product
5.1.1 COVID Vaccines - Market Size and Forecast (2021-2030)
5.1.2 Infectious Disease Vaccines - Market Size and Forecast (2021-2030)
5.1.3 Cancer Vaccines - Market Size and Forecast (2021-2030)
5.1.4 Autoimmune Diseases - Market Size and Forecast (2021-2030)
5.1.5 Others - Market Size and Forecast (2021-2030)
5.2 Competitive Scenario of Global mRNA Vaccine and Therapeutics Market: By End User
5.2.1 Hospitals & Clinics - Market Size and Forecast (2021-2030)
5.2.2 Research & Organizations - Market Size and Forecast (2021-2030)
5.2.3 Others - Market Size and Forecast (2021-2030)
6. Global mRNA Vaccine and Therapeutics Market: Regional Analysis
6.1 Competitive Scenario of Global mRNA Vaccine and Therapeutics Market: By Region
7. North America mRNA Vaccine and Therapeutics Market : An Analysis (2021-2030)
7.1 North America mRNA Vaccine and Therapeutics Market : Size and Forecast (2021-2030), By Value
7.2 North America mRNA Vaccine and Therapeutics Market - Prominent Companies
7.3 Market Segmentation By Product (COVID Vaccines, Infectious Disease Vaccines, Cancer Vaccines, Autoimmune Diseases, Others)
7.4 Market Segmentation End User (Hospitals & Clinics, Research & Organizations, Others)
7.5 North America mRNA Vaccine and Therapeutics Market: Country Analysis
7.6 Market Opportunity Chart of North America mRNA Vaccine and Therapeutics Market - By Country, By Value, 2030
7.7 Competitive Scenario of North America mRNA Vaccine and Therapeutics Market: By Country
7.8 United States mRNA Vaccine and Therapeutics Market: Size and Forecast (2021-2030), By Value
7.9 United States mRNA Vaccine and Therapeutics Market Segmentation - By Product, By End User (2021-2030)
7.10 Canada mRNA Vaccine and Therapeutics Market: Size and Forecast (2021-2030), By Value
7.11 Canada mRNA Vaccine and Therapeutics Market Segmentation - By Product, By End User (2021-2030)
8. Europe mRNA Vaccine and Therapeutics Market : An Analysis (2021-2030)
8.1 Europe mRNA Vaccine and Therapeutics Market : Size and Forecast (2021-2030), By Value
8.2 Europe mRNA Vaccine and Therapeutics Market - Prominent Companies
8.3 Market Segmentation By Product (COVID Vaccines, Infectious Disease Vaccines, Cancer Vaccines, Autoimmune Diseases, Others)
8.4 Market Segmentation End User (Hospitals & Clinics, Research & Organizations, Others )
8.5 Europe mRNA Vaccine and Therapeutics Market: Country Analysis
8.6 Market Opportunity Chart of Europe mRNA Vaccine and Therapeutics Market - By Country, By Value, 2030
8.7 Competitive Scenario of North America mRNA Vaccine and Therapeutics Market: By Country
8.8 Germany mRNA Vaccine and Therapeutics Market: Size and Forecast (2021-2030), By Value
8.9 Germany mRNA Vaccine and Therapeutics Market Segmentation - By Product, By End User (2021-2030)
8.10 United Kingdom mRNA Vaccine and Therapeutics Market: Size and Forecast (2021-2030), By Value
8.11 United Kingdom mRNA Vaccine and Therapeutics Market Segmentation - By Product, By End User (2021-2030)
8.12 France mRNA Vaccine and Therapeutics Market: Size and Forecast (2021-2030), By Value
8.13 France mRNA Vaccine and Therapeutics Market Segmentation - By Product, By End User (2021-2030)
8.14 Switzerland mRNA Vaccine and Therapeutics Market: Size and Forecast (2021-2030), By Value
8.15 Switzerland mRNA Vaccine and Therapeutics Market Segmentation - By Product, By End User (2021-2030)
8.16 Russia mRNA Vaccine and Therapeutics Market: Size and Forecast (2021-2030), By Value
8.17 Russia mRNA Vaccine and Therapeutics Market Segmentation - By Product, By End User (2021-2030)
9. Asia Pacific mRNA Vaccine and Therapeutics Market : An Analysis (2021-2030)
9.1 Asia Pacific mRNA Vaccine and Therapeutics Market : Size and Forecast (2021-2030), By Value
9.2 Asia Pacific mRNA Vaccine and Therapeutics Market - Prominent Companies
9.3 Market Segmentation By Product (COVID Vaccines, Infectious Disease Vaccines, Cancer Vaccines, Autoimmune Diseases, Others)
9.4 Market Segmentation End User (Hospitals & Clinics, Research & Organizations, Others )
9.5 Asia Pacific mRNA Vaccine and Therapeutics Market: Country Analysis
9.6 Market Opportunity Chart of Asia Pacific mRNA Vaccine and Therapeutics Market - By Country, By Value, 2030
9.7 Competitive Scenario of Asia Pacific mRNA Vaccine and Therapeutics Market: By Country
9.8 China mRNA Vaccine and Therapeutics Market: Size and Forecast (2021-2030), By Value
9.9 China mRNA Vaccine and Therapeutics Market Segmentation - By Product, By End User (2021-2030)
9.10 Japan mRNA Vaccine and Therapeutics Market: Size and Forecast (2021-2030), By Value
9.11 Japan mRNA Vaccine and Therapeutics Market Segmentation - By Product, By End User (2021-2030)
9.12 India mRNA Vaccine and Therapeutics Market: Size and Forecast (2021-2030), By Value
9.13 India mRNA Vaccine and Therapeutics Market Segmentation - By Product, By End User (2021-2030)
10. Global mRNA Vaccine and Therapeutics Market Dynamics
10.1 Drivers
10.2 Restraints
10.3 Trends
11. Market Attractiveness
11.1 Market Attractiveness Chart of Global mRNA Vaccine and Therapeutics Market - By Product, 2030
11.2 Market Attractiveness Chart of Global mRNA Vaccine and Therapeutics Market - By End User, 2030
11.3 Market Attractiveness Chart of Global mRNA Vaccine and Therapeutics Market - By Region, 2030
12. Competitive Landscape
12.1 Major Technological Innovations, Mergers & Acquisitions and Role of Manufacturers
13. mRNA Vaccine and Therapeutics Pipeline Development
13.1 mRNA vaccine development pipeline for infectious diseases
13.2 mRNA cancer therapies in development
13.3 mRNA-based protein therapeutics in development
14. Regulatory Compliance
15. Company Analysis
15.1 AstraZeneca Plc
15.2 Bayer Group
15.3 Boehringer Ingelheim
15.4 GlaxoSmithKline
15.5 Pfizer
15.6 Moderna
15.7 BioNtech
15.8 Sangamo Therapeutics
15.9 Crispr Therapeutics
15.10 Intellia TherapeuticsList of Figures
Figure 1: Global mRNA Vaccine and Therapeutics Market Size, By Value, 2021-2030 (USD Million)
Figure 2: Global Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 3: Global Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 4: Global Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 5: Global Expenses (% GDP), 2015-2019
Figure 6: GDP per Capita Growth (annual %), 2015-2019
Figure 7: World Population 65 Years & Above (% of Total), 2015-2019
Figure 8: Daily Covid-19 vaccine doses administered per 100 people , Feb 3, 2021 (In Millions)
Figure 9: Total no. of Covid-19 vaccination administered, Feb 3, 2021 (In Millions)
Figure 10: Share of people who received at least one dose of covid-19 vaccine, Feb 3, 2021 (In %)
Figure 11: Share of the population fully vaccinated against covid-19, Feb 3, 2021 (In %)
Figure 12: Global Number of deaths in 2020, all cancers, males and females, all ages, (In Numbers)
Figure 13: Global Number of Confirmed COVID19 Deaths, Feb 2021 (In Per Million People)
Figure 14: Global mRNA Vaccine and Therapeutics Market- By Product Market Share, 2025 & 2030
Figure 15: Global mRNA Vaccine and Therapeutics Market- By COVID vaccines, By Value (USD Million), 2021-2030
Figure 16: Global mRNA Vaccine and Therapeutics Market- By Infectious Disease vaccines, By Value (USD Million), 2021-2030
Figure 17: Global mRNA Vaccine and Therapeutics Market- By Cancers vaccines, By Value (USD Million), 2021-2030
Figure 18: Global mRNA Vaccine and Therapeutics Market- By Autoimmune Diseases, By Value (USD Million), 2021-2030
Figure 19: Global mRNA Vaccine and Therapeutics Market- By Others, By Value (USD Million), 2021-2030
Figure 20: Global mRNA Vaccine and Therapeutics Market- By End User Market Share, 2025 & 2030
Figure 21: Global mRNA Vaccine and Therapeutics Market- By Hospitals & Clinics, By Value (USD Million), 2021-2030
Figure 22: Global mRNA Vaccine and Therapeutics Market- By Research Organizations, By Value (USD Million), 2021-2030
Figure 23: Global mRNA Vaccine and Therapeutics Market- By Others, By Value (USD Million), 2021-2030
Figure 24: Global mRNA Vaccine and Therapeutics Market- By Region Market Share, 2025 & 2030
Figure 25: North America mRNA Vaccine and Therapeutics Market Size, By Value, 2021-2030 (USD Million)
Figure 26: North America Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 27: North America Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 28: North America Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 29: North America Urban population, 2015-2018 (In %)
Figure 30: North America Number of Confirmed COVID19 Deaths, Feb 2021 (In Per Million People)
Figure 31: North America mRNA Vaccine and Therapeutics Market- By Product, By Value (USD Million), 2021-2030
Figure 32: North America mRNA Vaccine and Therapeutics Market- By End User, By Value (USD Million), 2021-2030
Figure 33: Market Opportunity Chart of North America mRNA Vaccine and Therapeutics Market- By Country, By Value (Year-2030
Figure 34: North America mRNA Vaccine and Therapeutics Market- By Country Market Share, 2025 & 2030
Figure 35: United States mRNA Vaccine and Therapeutics Market Size, By Value, 2021-2030 (USD Million)
Figure 36: United State Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 37: United State Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 38: United State Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 39: United States Urban population, 2016-2019 (In %)
Figure 40: United State mRNA Vaccine and Therapeutics Market- By Product, By Value (USD Million), 2021-2030
Figure 41: United State mRNA Vaccine and Therapeutics Market- By End User, By Value (USD Million), 2021-2030
Figure 42: Canada mRNA Vaccine and Therapeutics Market Size, By Value, 2016-2026 (USD Million)
Figure 43: Canada Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 44: Canada Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 45: Canada Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 46: Canada Urban population, 2015-2019 (In %)
Figure 47: Canada mRNA Vaccine and Therapeutics Market- By Product, By Value (USD Million), 2021-2030
Figure 48: Canada mRNA Vaccine and Therapeutics Market- By End User, By Value (USD Million), 2021-2030
Figure 49: Europe mRNA Vaccine and Therapeutics Market Size, By Value, 2016-2026 (USD Million)
Figure 50: Europe Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 51: Europe Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 52: Europe Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 53: Europe Urban population, 2015-2019 (In %)
Figure 54: Europe Number of Confirmed COVID19 Deaths, Feb 2021 (In Per Million People)
Figure 55: Europe mRNA Vaccine and Therapeutics Market- By Product, By Value (USD Million), 2021-2030
Figure 56: Europe mRNA Vaccine and Therapeutics Market- By End User, By Value (USD Million), 2021-2030
Figure 57: Market Opportunity Chart of Europe mRNA Vaccine and Therapeutics Market- By Country, By Value (Year-2030)
Figure 58: Europe mRNA Vaccine and Therapeutics Market- By Country Market Share, 2025 & 2030
Figure 59: Germany mRNA Vaccine and Therapeutics Market Size, By Value, 2021-2030 (USD Million)
Figure 60: Germany Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 61: Germany Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 62: Germany Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 63: Germany Urban population, 2015-2019 (In %)
Figure 64: Germany mRNA Vaccine and Therapeutics Market- By Product, By Value (USD Million), 2021-2030
Figure 65: Germany mRNA Vaccine and Therapeutics Market- By End User, By Value (USD Million), 2021-2030
Figure 66: United Kingdom mRNA Vaccine and Therapeutics Market Size, By Value, 2021-2030 (USD Million)
Figure 67: United Kingdom Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 68: United Kingdom Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 69: United Kingdom Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 70: United Kingdom Urban population, 2015-2019 (In %)
Figure 71: United Kingdom mRNA Vaccine and Therapeutics Market- By Product, By Value (USD Million), 2021-2030
Figure 72: United Kingdom mRNA Vaccine and Therapeutics Market- By End User, By Value (USD Million), 2021-2030
Figure 73: France mRNA Vaccine and Therapeutics Market Size, By Value, 2021-2030 (USD Million)
Figure 74: France Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 75: France Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 76: France Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 77: France Urban population, 2015-2019 (In %)
Figure 78: France mRNA Vaccine and Therapeutics Market- By Product, By Value (USD Million), 2021-2030
Figure 79: France mRNA Vaccine and Therapeutics Market- By End User, By Value (USD Million), 2021-2030
Figure 80: Switzerland mRNA Vaccine and Therapeutics Market Size, By Value, 2021-2030 (USD Million)
Figure 81: Switzerland Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 82: Switzerland Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 83: Switzerland Domestic Private Health Expenditure as % of Current Health
Figure 84: Switzerland Domestic Government Health Expenditure as % of GDP, 2015-2018 (In %)
Figure 85: Switzerland mRNA Vaccine and Therapeutics Market- By Product, By Value (USD Million), 2021-2030
Figure 86: Switzerland mRNA Vaccine and Therapeutics Market- By End User, By Value (USD Million), 2021-2030
Figure 87: Russia mRNA Vaccine and Therapeutics Market Size, By Value, 2021-2030 (USD Million)
Figure 88: Russia Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 89: Russia Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 90: Russia Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 91: Russia Domestic Government Health Expenditure as % of GDP, 2015-2018 (In %)
Figure 92: Russia mRNA Vaccine and Therapeutics Market- By Product, By Value (USD Million), 2021-2030
Figure 93: Russia mRNA Vaccine and Therapeutics Market- By End User, By Value (USD Million), 2021-2030
Figure 94: Asia Pacific mRNA Vaccine and Therapeutics Market Size, By Value, 2021-2030 (USD Million)
Figure 95: Asia Pacific Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 96: Asia Pacific Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 97: Asia Pacific Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 98: Asia Pacific Urban population, 2015-2019 (In %)
Figure 99: Asia pacific Number of Confirmed COVID19 Deaths, Feb 2021 (In Per Million People)
Figure 100: Asia Pacific mRNA Vaccine and Therapeutics Market- By Product, By Value (USD Million), 2021-2030
Figure 101: Asia Pacific mRNA Vaccine and Therapeutics Market- By End User, By Value (USD Million), 2021-2030
Figure 102: Market Opportunity Chart of APAC mRNA Vaccine and Therapeutics Market- By Country, By Value (Year-2030)
Figure 103: APAC mRNA Vaccine and Therapeutics Market- By Country Market Share, 2025 & 2030
Figure 104: China mRNA Vaccine and Therapeutics Market Size, By Value, 2021-2030 (USD Million)
Figure 105: China Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 106: China Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 107: China Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 108: China Urban Population (%) of total population, 2016-2020
Figure 109: China mRNA Vaccine and Therapeutics Market- By Product, By Value (USD Million), 2021-2030
Figure 110: China mRNA Vaccine and Therapeutics Market- By End User, By Value (USD Million), 2021-2030
Figure 111: Japan mRNA Vaccine and Therapeutics Market Size, By Value, 2021-2030 (USD Million)
Figure 112: Japan Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 113: Japan Current Healthcare Expenditure as percentage of GDP, 2015-2018 (In %)
Figure 114: Japan Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 115: Japan Urban Population (%) of total population, 2016-2020
Figure 116: Japan mRNA Vaccine and Therapeutics Market- By Product, By Value (USD Million), 2021-2030
Figure 117: Japan mRNA Vaccine and Therapeutics Market- By End User, By Value (USD Million), 2021-2030
Figure 118: India mRNA Vaccine and Therapeutics Market Size, By Value, 2021-2030 (USD Million)
Figure 119: India Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 120: India Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 121: India Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 122: India Urban Population (%) of total population, 2016-2020
Figure 123: India mRNA Vaccine and Therapeutics Market- By Product, By Value (USD Million), 2021-2030
Figure 124: India mRNA Vaccine and Therapeutics Market- By End User, By Value (USD Million), 2021-2030
Figure 125: Market Attractiveness Chart of Global mRNA Vaccine and Therapeutics Market- By Product (Year-2030)
Figure 126: Market Attractiveness Chart of Global mRNA Vaccine and Therapeutics Market- By End User (Year-2030)
Figure 127: Market Attractiveness Chart of Global mRNA Vaccine and Therapeutics Market- By Region (Year-2030)
Figure 128: AstraZeneca Sales Revenues, 2016-2020 (USD Million)
Figure 129: AstraZeneca Gross Profit, 2016-2020 (USD Million)
Figure 130: AstraZeneca Plc Sales Revenue Split, By Business Segment (%), FY2020
Figure 131: AstraZeneca Plc Sales Revenue Split, By Geography Segment (%), FY2020
Figure 132: Bayer Group Revenues, 2016-2020 (USD Million)
Figure 133: Bayer Group Net Income, 2016-2020 (USD Million)
Figure 134: Bayer Group Sales Revenue Split, By Business Segment (%), FY2020
Figure 135: Bayer Group Sales Revenue Split, By Geography Segment (%), FY2020
Figure 136: Boehringer Ingelheim Revenues, 2016-2020 (USD Million)
Figure 137: Boehringer Ingelheim Net Income/Loss, 2016-2020 (USD Million)
Figure 138: Boehringer Ingelheim Sales Revenue Split, By Business Segment (%), FY2020
Figure 139: Boehringer Ingelheim Sales Revenue Split, By Geography Segment (%), FY2020
Figure 140: GlaxoSmithKline Annual Sales Revenue (USD Million), 2016-2020
Figure 141: GlaxoSmithKline Net Profit (USD Million), 2016-2020
Figure 142: GlaxoSmithKline Sales Revenue Split, By Business Segment (%), FY2020
Figure 143: GlaxoSmithKline Sales Revenue Split, By Geography Segment (%), FY2020
Figure 144: Pfizer Annual Sales Revenue (USD Million), 2016-2020
Figure 145: Pfizer Annual Net Income/Loss (USD Million), 2016-2020
Figure 146: Pfizer Sales Revenue Split, By Geography Segment (USD Million), FY2020
Figure 147: Pfizer Sales Revenue Split, By Geography Segment (USD Million), FY2019
Figure 148: Moderna Annual Sales Revenue (USD Million), 2016-2020
Figure 149: Moderna collaboration Revenue (USD Million), 2016-2020
Figure 150: Moderna Sales Revenue Split, By Geography Segment (USD Million), FY2020
Figure 151: Moderna Sales Revenue Split, By Geography Segment (USD Million), FY2019
Figure 152: BioNTECH Annual Sales Revenue (USD Million), 2017-2020
Figure 153: BioNTECH Profit/Loss (USD Million), 2017-2020
Figure 154: BioNTech Sales Revenue Split, By Operating Segment (USD Million), FY2020
Figure 155: BioNtech Sales Revenue Split, By Operating Segment (USD Million), FY2019
Figure 156: Sangamo Therapeutics Annual Sales Revenue (USD Million), 2016-2020
Figure 157: Sangamo Therapeutics Net Loss (USD Million), 2016-2020
Figure 158: Crispr Therapeutics Collaboration Revenue (USD Million), 2015-2019
Figure 159: Crispr Therapeutics Net Income (USD Million), 2015-2019
Companies Mentioned
- AstraZeneca Plc
- Bayer Group
- Boehringer Ingelheim
- GlaxoSmithKline
- Pfizer
- Moderna
- BioNtech
- Sangamo Therapeutics
- Crispr Therapeutics
- Intellia Therapeutics.
Table Information
| Report Attribute | Details |
|---|---|
| Published | May 2021 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 34.1 Billion |
| Forecasted Market Value ( USD | $ 85.3 Billion |
| Compound Annual Growth Rate | 25.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
